1. Comas D, Mateu J. Treatment of extravasation of both doxorubicin and vincristine administration in a Y-site infusion. Ann. Pharmacother. 1996; 30:244-246.
2. Yalkowsky SH, Krzyzaniak JF, Ward GH. Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 1998; 87:787-796.
3. Puntis JWL. The economics of home parenteral nutrition. Nutr. 1998; 14:809-812.
4. Chung DH, Ziegler MM. Central venous catheter access. Nutr. 1998; 14:119-123.
5. Macfie J. Infusion phlebitis and peripheral parenteral nutrition. Nutr. 1998; 14:233-235.
6. Plusa SM, Webster N, Horsman R, Primrose JN, Kendall-Smith S. Fine-bore cannulas for peripheral intravenous nutrition: polyurethaneor silicone? Ann. Royal College Surg. England 1998; 80:154-156.
7. Brown KT, Nevins AB, Getrajdman GI, Brody LA, Kurtz RC, Fong YM, et al. Particle embolization for hepatocellular carcinoma. J. Vasc. Intervent. Radiol. 1998; 9:822-828.
8. Hunter RJ. Foundations of colloid science. New York: Oxford University Press, 1997.
9. Washington C. The stability of intravenous fat emulsions in total parenteral-nutrition mixtures. Int. J. Pharmaceut. 1990; 66:1-21.
10. Kellaway IW, Seale L, Spencer PSJ. The in vitro characterization and biostability of Tc-99m-dextran and its accumulation within the inflamed paws of adjuvant-induced arthritic rats. Pharm. Res. 1995; 12:588-593.
11. Illum L, Davis SS. The organ uptake of intravenously administered colloidal particles can be altered using a non-ionic surfactant (Poloxamer-338). Febs Letters 1984; 167:79-82.
12. Woodle MC, Newman MS, Collins LR, Martin FJ. Efficient evaluation of long circulating or stealth liposomes by studies of in vivo blood-circulation kinetics and final organ distribution in rats. Biophys. J. 1990; 57:A261.
13. Clark LC, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 1966; 152:1755-1756.
14. Krafft MP, Reiss JG, Weers JG. The design and engineering of oxygen-delivering fluorocarbon emulsions. In: Benita S, ed. Submicron Emulsions in Drug Delivery and Targeting. Netherlands: Harwood Academic Publishers, 1998:235-333.
15. Chang TMS. Recent and future developments in modified hemoglobin and microencapsulated hemoglobin as red blood cell substitutes. Artif. Cells Blood Substit. Immobiliz. Biotechnol. 1997; 25:1-24.
16. Rabinovici R, Rudolph AS, Vernick J, Feuerstein G. Lyophilized liposome-encapsulated hemoglobin—evaluation of hemodynamic, biochemical, and hematologic responses. Crit. Care Med. 1994; 22:480-485.
17. Bonetti A, Chatelut E, Kim S. An Extended-Release Formulation of methotrexate for subcutaneous administration. Cancer Chemotherap. Pharmacol. 1994; 33:303-306.
18. Kuzma P, Moo Young AJ, Moro D, Quandt H, Bardin CW, Schlegel PH. Subcutaneous hydrogel reservoir system for controlled drug delivery Macromol. Symp. 1996; 109:1526.
19. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block copolymers as injectable drug-Del. systems. Nature 1997; 388(6645):860-862.
20. Ousseren C, Storm G. Targeting to lymph nodes by subcutaneous administration of liposomes. Int. J. Pharmaceut. 1998; 162:39-44.
21. Schanker LS, Morrison AS. Physiological disposition of guanethidine in the rat and its uptake by heart slices. Int. J. Neuropharmacol. 1965; 4:27-39.
22. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Del. Rev. 1999; 36:179-194.
23. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurg. 1998; 42:1083-1099.
24. Levin VA. Relationship of octanol-water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 1990; 23:682-684.
25. Greig NH, Soncrant TT, Shetty HU, Momma S, Smith QR, Rapoport SI. Brain uptake and anti-cancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemotherap. Pharmacol. 1990; 26:263-268.
26. Tsuji A, Tamai I. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Del. Rev. 1999; 36:277-290.
27. Wade LA, Katzman R. Synthetic amino-acids and the nature of L-dopa transport at the blood-brain barrier. J. Neurochem. 1975; 25:837-842.
28. Pardridge WM, Buciak JL, Friden PM. Selective transport of an antitransferrin receptor antibody through the blood brain barrier in vivo. J. Pharmacol. Exp. Therapeut. 1991; 259:66-70.
29. Bickel U, Yoshikawa T, Landaw EM, Faull KF, Pardridge WM. Pharmacological effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Nat. Acad. Sci. U.S.A. 1993; 90:2618-2622.
30. Boado RJ, Tsukamoto H, Pardridge WM. Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J. Pharma. Sci. 1998; 87:1308-1315.
31. Pardridge WM. Peptide Drug Delivery to the Brain. New York: Raven Press, 1991.
32. Bickel U, Lee VMY, Trojanowski JQ, Pardridge WM. Development and in vitro characterization of a cationized monoclonal-antibody against Beta-A4 protein—a potential probe for Alzheimers disease. Bioconj. Chem. 1994; 5:119-125.
33. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Cont. Rel. 1997; 49:81-87.
34. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 1998; 87:1305-1307.
Was this article helpful?
Download this Guide and Discover 50 Ways To Treat Acne Using Only Natural Remedies. About Time You Got Rid of Your Acne? Inside this guide, you'll discover: 50 ways to treat acne using natural remedies. The benefits of treating acne using natural remedies. Natural acne remedies to treat acne scarring. The side effects of popular acne medicines and treatments plus much, much more.